How to Safely Stop Evenity (Romosozumab): Discontinuation Protocol

Why Romosozumab Has a Built-In Expiration Date

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP) and decreases bone resorption markers (CTX), a dual effect no other approved osteoporosis drug replicates 1. This "anabolic window" closes on its own.

Bone formation markers peak around month 6 and return toward baseline by month 12, even while the patient is still receiving injections. The FDA prescribing information specifies a lifetime exposure of 12 doses because extending treatment has not shown additional BMD benefit. Continued dosing beyond 12 months simply exposes patients to cardiovascular risk (the boxed warning cites a higher rate of major adverse cardiac events compared with alendronate in the ARCH trial) without corresponding skeletal benefit 2.

The bone biology here is straightforward. Sclerostin suppression triggers a burst of osteoblast activity. That burst is self-limiting. Once the new bone is laid down, the treatment's job is done. The next job belongs to an antiresorptive.

What Happens to Bone if You Simply Stop

Bone density gained during romosozumab erodes rapidly without consolidation therapy. The FRAME extension study showed that patients who received romosozumab for 12 months followed by placebo lost the majority of their lumbar spine BMD gains within 12 months 3. This pattern mirrors what happens after stopping teriparatide (Forteo). Anabolic agents build bone; they do not lock it in place.

Data from the FRAME trial (N=7,180) showed that women who transitioned from romosozumab to denosumab continued gaining BMD through month 24, reaching 17.6% at the lumbar spine. Women who transitioned from placebo to denosumab gained only 5.0% over the same period 3. The gap between these two groups represents the romosozumab-specific gains that denosumab preserved.

Without follow-on therapy, patients can return to pre-treatment fracture risk within 1 to 2 years. This is not a theoretical concern. The Endocrine Society 2024 clinical practice guideline explicitly states that anabolic therapy should always be followed by antiresorptive treatment to maintain BMD gains and reduce fracture risk 4.

The ARCH Trial: Romosozumab Followed by Alendronate

The ARCH trial (N=4,093) is the key study for understanding the romosozumab-to-bisphosphonate sequence. Postmenopausal women with osteoporosis and a fragility fracture received either romosozumab 210 mg monthly or alendronate 70 mg weekly for 12 months, then both groups transitioned to open-label alendronate 1.

At 24 months (12 months of romosozumab followed by 12 months of alendronate), the romosozumab-to-alendronate group had a 48% lower risk of new vertebral fracture compared to the alendronate-only group (relative risk 0.52 to 95% CI 0.40 to 0.66, P<0.001). Hip fracture risk dropped by 38% 1.

These results established two facts. First, romosozumab produces fracture protection that persists into the bisphosphonate phase. Second, transition to alendronate is a validated and effective sequencing strategy.

The cardiovascular signal in ARCH (higher rates of adjudicated major adverse cardiac events in the romosozumab arm during the first 12 months) led to the boxed warning. This signal was not seen in FRAME, where the comparator was placebo rather than alendronate 5. The clinical implication: the cardiovascular risk applies to the 12-month treatment period, not to the post-transition antiresorptive phase.

Step-by-Step Discontinuation Protocol

The following protocol reflects consensus from the Endocrine Society guideline, the AACE/ACE 2020 clinical practice guideline, and published transition data from FRAME and ARCH.

Month 11 (one month before final dose): Schedule the transition plan. Order a DXA scan if not performed since month 0. Review cardiovascular history and renal function to guide follow-on drug selection. Discuss the two primary transition options with the patient.

Month 12 (final romosozumab injection): Administer the 12th dose. Confirm the follow-on therapy choice. If denosumab, schedule the first injection for 1 month after the last romosozumab dose. If oral bisphosphonate, start the prescription within 1 month.

Month 13 (transition initiation): Begin antiresorptive therapy. The gap between the last romosozumab dose and the first antiresorptive dose should not exceed 1 month to avoid a resorption flare.

Month 24 (12 months post-transition): Repeat DXA scan. Compare to the month 0 and month 12 baselines. If BMD is stable or increasing, the consolidation strategy is working. If BMD has dropped by more than 3% to 5% at any site, reassess treatment adherence and consider switching antiresorptive class.

Ongoing monitoring: Check serum calcium and 25-hydroxyvitamin D at transition and again at 6 months. Ensure vitamin D is above 30 ng/mL and calcium intake is 1,000 to 1 to 200 mg daily (diet plus supplementation if needed) 6.

Denosumab vs. Bisphosphonate as Follow-On Therapy

Both denosumab and bisphosphonates preserve the BMD gains from romosozumab. The choice depends on patient-specific factors.

Denosumab (Prolia, 60 mg SC every 6 months): The FRAME extension data showed that romosozumab followed by denosumab produced the largest cumulative BMD gains: 17.6% at the lumbar spine and 8.8% at the total hip at 24 months 3. Denosumab may be preferred for patients with renal impairment (eGFR <35 mL/min), where bisphosphonates are contraindicated or require dose adjustment. The tradeoff: denosumab itself carries a rebound resorption risk if later discontinued without bisphosphonate bridging. Selecting denosumab as the follow-on creates a downstream commitment to either indefinite injections or a planned bisphosphonate exit ramp 7.

Alendronate (70 mg oral weekly): ARCH validated this sequence directly. Alendronate is generic, inexpensive, and has a long skeletal half-life, meaning it continues suppressing resorption for months to years even after discontinuation. This makes it the simpler exit strategy. Alendronate requires adequate renal function (eGFR ≥35 mL/min), the ability to sit upright for 30 minutes after dosing, and the absence of esophageal disorders 1.

Zoledronic acid (5 mg IV once yearly): A reasonable alternative for patients who cannot tolerate oral bisphosphonates. No large trial has specifically studied the romosozumab-to-zoledronate sequence, but the pharmacologic rationale is sound: zoledronate is the most potent antiresorptive bisphosphonate and achieves near-complete suppression of bone resorption with a single annual infusion 8. The AACE 2020 guideline lists it as an acceptable follow-on option 6.

How Romosozumab Works: Sclerostin Inhibition Explained

Sclerostin is a glycoprotein produced almost exclusively by osteocytes, the long-lived cells embedded within mineralized bone. Sclerostin binds to LRP5/6 co-receptors on osteoblast precursors and inhibits the Wnt signaling pathway. When Wnt signaling is suppressed, osteoblast differentiation slows and bone formation drops 9.

Romosozumab is a humanized IgG2 monoclonal antibody that binds and neutralizes sclerostin. The result is a rapid increase in Wnt-mediated osteoblast activity. P1NP (a bone formation marker) rises by roughly 140% above baseline within the first month of treatment. CTX (a bone resorption marker) decreases by approximately 55% during the same period 5.

This dual mechanism is unique among osteoporosis therapies. Teriparatide and abaloparatide increase formation but also increase resorption over time. Bisphosphonates and denosumab decrease resorption but do not stimulate formation. Romosozumab does both simultaneously, which explains the speed and magnitude of BMD gains: 13.3% at the lumbar spine in just 12 months, approximately double the gain from two years of teriparatide 5.

The self-limiting nature of the response appears to relate to a compensatory upregulation of Dickkopf-1 (DKK1) and other Wnt antagonists that re-establish baseline signaling tone. This biological ceiling is why the FDA label specifies 12 doses, not indefinite treatment.

Populations That Need Extra Caution at Discontinuation

Patients with prior vertebral fracture. These patients are at highest absolute fracture risk and stand to lose the most from a gap in therapy. The American Association of Clinical Endocrinology (AACE) classifies patients with a recent vertebral fracture as "very high risk" and recommends anabolic-first sequencing followed by immediate antiresorptive consolidation with no treatment gap 6.

Patients with cardiovascular disease. The boxed warning applies during romosozumab treatment. Stopping romosozumab removes the cardiovascular exposure, but clinicians should still document a cardiovascular risk assessment at the transition visit, especially before initiating denosumab (which requires ongoing injections and thus ongoing clinic contact) 2.

Glucocorticoid users. Long-term corticosteroid use accelerates bone loss through multiple pathways. These patients may lose romosozumab-derived BMD gains faster than the general population. The 2017 American College of Rheumatology guideline recommends strong antiresorptive therapy for patients on prednisone ≥2.5 mg daily for ≥3 months 10. Transition to denosumab or zoledronic acid (rather than oral alendronate) may offer more reliable resorption suppression in this group.

Patients with chronic kidney disease (CKD stage 4 to 5). Bisphosphonates are generally avoided when eGFR is below 30 to 35 mL/min due to accumulation risk. Denosumab does not depend on renal clearance, making it the preferred follow-on agent in advanced CKD. However, denosumab carries a higher risk of hypocalcemia in CKD, so serum calcium must be corrected and monitored closely before each injection 7.

Monitoring Bone Turnover Markers After Transition

DXA remains the standard for tracking treatment response, but bone turnover markers (BTMs) can provide earlier signals. CTX (C-terminal telopeptide) reflects osteoclast-mediated resorption and responds within weeks to antiresorptive therapy. P1NP reflects osteoblast activity and should normalize from its romosozumab-elevated peak after the last dose.

A practical monitoring approach: check fasting serum CTX at the transition visit (month 12 to 13) and again at 3 to 6 months on the new antiresorptive. If CTX drops below 200 pg/mL, the antiresorptive is working as expected. If CTX remains elevated, assess medication adherence (especially for oral bisphosphonates taken incorrectly) or consider switching to a parenteral agent 6.

P1NP is less useful for monitoring the transition because it naturally falls as romosozumab clears. A persistently elevated P1NP more than 6 months after the last romosozumab dose could indicate high bone turnover not being controlled by the follow-on therapy.

When Retreatment with Romosozumab Might Be Considered

The FDA label does not currently support a second course of romosozumab. Limited data exist on retreatment. A phase 2 extension study showed that patients who received romosozumab, then placebo for 12 months, then a second course of romosozumab regained BMD, though the magnitude of gain was smaller than the first course 11. Anti-romosozumab antibodies were detected in roughly 18% of patients but were not neutralizing and did not appear to blunt efficacy.

Retreatment remains off-label. The 2024 Endocrine Society guideline does not recommend routine retreatment but acknowledges it as an area of active investigation 4. Clinicians considering retreatment should document the rationale, confirm ongoing very-high fracture risk, and re-evaluate cardiovascular status.

Clinical Bottom Line

Every patient completing 12 doses of romosozumab should begin an antiresorptive within 1 month. Alendronate 70 mg weekly and denosumab 60 mg every 6 months are the two evidence-backed options. Repeat DXA at 12 months post-transition to confirm BMD preservation. For patients on glucocorticoids or with CKD stage 4 to 5, denosumab is preferred. The minimum acceptable monitoring includes DXA, serum calcium, and 25-hydroxyvitamin D at transition and annually thereafter.